Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
108.48
(
0.32%
)
Bitcoin
68,698.36
(
1.27%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ThomasS

Send PM Follow Ignore
Followers 12
Posts 2277
Boards Moderated 0
Alias Born 05/05/2005

ThomasS

Re: None

Wednesday, 10/11/2006 9:04:18 AM

Wednesday, October 11, 2006 9:04:18 AM

Post# of 257269
ADH Adherex regains all rights to ADH-1 (21.55 )

Co announces that the GlaxoSmithKline (GSK) one-time option to license ADH-1 has expired unexercised. As a result, ADH has regained all rights relating to ADH-1 and will continue with the clinical development of the compound. The license agreement with GSK relating to eniluracil remains unchanged

"Illegitimacy is something we should talk about in terms of not having it."

- Dan Quayle

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today